The fact that activation of MRCKα by either gene transfer or overexpression of the β1-Na+, K+-ATPase in lungs with existing injury is able to treat the disease provides a rationale for developing easier to administer pharmacological agents to activate MRCKα for ARDS. This evidence concerns the gene CDC42BPA and acute respiratory distress syndrome.